x

Search for a clinical trial

* (*) mandatory field

A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy (Phase III) - FR

  • Type of clinical trial : Drug clinical trial
  • Recruiting project : No
  • Status : Terminated trial
  • Funded by an IRDiRC member
  • Funding body(ies) :
  • Geographic coverage : Global
  • Sponsor : Ptc therapeutics, inc.
  • Website
    • Phase : III
  • Principal investigator of clinical trial

  • Dr Robert SPIEGEL
  • PTC Therapeutics Inc.
  • 100 Corporate Court
  • SOUTH PLAINFIELD NJ 07080-2449
  • UNITED STATES
  • More information
  • Phone  : 190 82 22 70 00
  • Fax  : 190 82 22 72 31
  • Website
  • Contact secretary  :
Last update: May 2017

Part of a multinational clinical trial

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.